In the SUISSE MPC 2 study (Stress Urinary Incontinence Study to assess Safety and Efficacy of Muvon’s Muscle Precursor Cell Therapy), researchers at the University of Zurich are currently investigating a novel treatment option. This is a so-called “Phase II study”, which is designed to assess the efficacy and safety of the new treatment option.
Muvon Therapeutics is urgently looking for patients who are willing to take part in this trial in Switzerland.
It is a novel treatment under development that uses the patient’s own muscle precursor cells to regenerate the damaged urinary sphincter muscle aiming to improve the condition without the use of implanted synthetic material and surgery with possible associated complications.
Please find below some information about this study in German
The MPC Therapy is a novel regenerative approach which aims to improve the symptoms of stress urinary incontinence without the use of synthetic material.
For more information on the treatment and the phase II clinical trial investigating its safety and efficacy please watch the following video or visit www.muvon-trials.com
The safety and efficacy of the MPC Therapy is currently being investigated in a phase II clinical trial at the University Hospital in Zurich. To find out more and check your eligibility for joining the trial please visit. www.muvon-trials.com